Debiopharm to Reveal Insights From Their ADC, DDR Inhibitor, and Antibody Conjugation Technology Research at the 2025 AACR Conference in Chicago

Contributed by: Business Wire

Logo

Tags

Health Technology

Electronic Design Automation

Manufacturing

Technology

Stem Cells

Radiology

Pharmaceutical

Oncology

Genetics

Artificial Intelligence

Clinical Trials

Other Manufacturing

Biotechnology

Science

Research

Health

biopharmaceutical

More Like This

Debiopharm to Showcase Research Results of Their DDR Inhibitors at the 2024 AACR Conference in San Diego

Debiopharm and Genome & Company Reach Agreement for Potential First-In Class Oncology Antibody Drug Conjugate Family

Debiopharm and Oncodesign Services Launch Strategic Collaboration to Propel Radiopharmaceuticals in Preclinical Research

Debiopharm Extends SunRock Biopharma Partnership for Antibody Drug Conjugates Targeting HER3 in EGFR Mutated Cancers

MEDSIR & Debiopharm Initiate Clinical Collaboration to Explore Potential Synergy of Debio 0123 & Sacituzumab Govitecan in Advanced Breast Cancer

Debiopharm Launches Expansion of WEE1 Inhibitor Monotherapy Research in Gynecological Cancers and Other Biomarker-driven Solid Tumors

Debiopharm to Showcase Research Results of Their First-in-class Anti-staphylococcal Program at IDWeek 2024 in Los Angeles

Biocytogen Enters Collaboration with ABL Bio to Develop New Bispecific Antibody-Drug Conjugates